Blend / Metabolic

CagriSema (Cagrilintide + Semaglutide)

Next-generation weight loss combination. GLP-1 agonist Semaglutide with long-acting amylin analogue Cagrilintide.

Build protocol outline Open dose calculator TNHL ebooks

Educational reference only. This page does not diagnose, prescribe, or replace care from a licensed professional. Laws, availability, and clinical appropriateness vary by location.

Reference dose5mg each per vial. Titrate from 0.25mg weekly. Follow GLP-1 protocol.

Half-life168 hours

Risk flagmoderate

Regulatory noteResearch-only flag

Side effects and watch-outs

Nausea
Vomiting
Diarrhoea
Constipation
Injection site reaction